NATR Q3 2026 deep dive: management cites China weakness and digital normalization for underperformance
Wellness products company Nature’s Sunshine (NASDAQ:NATR) fell short of the market’s revenue expectations in Q3 2026, with sales falling 9.1% year on year to $116.6 million. The company’s full-year revenue guidance of $465 million at the midpoint came in 6.2% below analysts’ estimates. Its non-GAAP profit of $0.14 per share was 44% below analysts’ consensus estimates.
Is now the time to buy NATR? Find out in our full research report (it’s free for active Edge members).
Nature's Sunshine (NATR) Q3 2026 highlights:
- Revenue $116.6 million vs S&P analysts’ estimates of $129.5 million (9.1% year-on-year decline, 10% miss)
- Adjusted EPS $0.14 vs S&P analysts’ expectations of $0.25 (44% miss)
- Adjusted EBITDA $11.14 million vs analyst estimates of $12.16 million (9.6% margin, 8.4% miss)
- Revenue guidance The company dropped its revenue guidance for the full year to $465 million at the midpoint from $495 million, a 6.1% decrease
- EBITDA guidance $46 million at the midpoint for the full year, below analyst estimates of $50.86 million
- Operating margin 4.5%, down from 7% in the same quarter last year
- Market capitalization $225.9 million
StockStory’s take
Nature’s Sunshine’s third quarter was marked by a pronounced decline in both revenue and profitability, as the company missed Wall Street’s expectations. CEO Ken Romanzi was forthright in attributing the shortfall to persistent challenges in Asia—primarily China—and a slowdown in North American digital sales, both of which had previously been reliable growth drivers. Romanzi acknowledged, “We had a poor quarter that fell well short of our expectations,” and emphasized that operational disruptions in China, including the loss of key leadership and tightened distributor practices, significantly affected performance.
Looking forward, management’s guidance reflects continued caution as the company works through headwinds in its Asian and North American businesses. Romanzi outlined plans to invest further in digital infrastructure, expand geographic presence, and revamp the U.S. direct selling business with new product launches and compensation models. CFO Ruth Perkins noted that, while challenges are expected to persist in the near term, Nature’s Sunshine remains focused on strengthening its consultant base and pursuing growth opportunities, especially in emerging health categories like gut and women’s health.
Key insights from management’s remarks
Management attributed the disappointing quarter to weak sales in China and Taiwan, digital business normalization, and consultant disruptions, while emphasizing progress in recurring revenue and new regional initiatives.
- China leadership disruptions: Sales in China were significantly impacted by the unexpected passing of two key leaders and stricter enforcement of distributor practices. Management expects it will take several quarters to rebuild its consultant base and restore momentum in the region.
- Taiwan consultant base decline: Taiwan, traditionally a strong market, continued to show weakness due to a shrinking consultant base. New recruiting efforts have been initiated to counteract this trend, though near-term recovery is uncertain.
- Digital business normalization: North American digital sales, which had posted rapid expansion in recent years, experienced their first decline this quarter as the company lapped a viral product and adjusted to more normalized TikTok and e-commerce growth rates. Romanzi noted challenges with paid search effectiveness due to the rise of AI-driven search agents, and the company is investing in SaaS tools to adapt.
- Recurring revenue strength: Despite the slowdown, subscription autoship rates improved, with autoship representing 40% of digital sales and 53% of social commerce revenue, up sharply from prior years. This signals a shift toward a more stable, recurring revenue base.
- New CFO transition: The appointment of Ruth Perkins as CFO was highlighted as a key management change, with leadership expressing confidence in her ability to help guide Nature’s Sunshine back to profitable growth.
Drivers of future performance
Nature’s Sunshine’s outlook is shaped by efforts to recover in Asia, invest in digital channels, and introduce targeted product innovations, while managing ongoing margin pressures.
- Continued China and Taiwan headwinds: Management expects China’s sales challenges to persist, citing the need to rebuild the consultant base and adapt to new compliance standards. Taiwan’s recovery will depend on successful implementation of new recruitment strategies and revitalization of consultant engagement, but both markets remain unpredictable in the near term.
- Digital and direct selling transformation: The company plans to increase investment in digital marketing, improve its e-commerce platform, and launch a reimagined direct selling program in the U.S. by mid-next year. These initiatives include new product bundles, compensation structures, and recruitment incentives aimed at reigniting growth in North America.
- Product innovation focus: Launches in high-growth health categories are a cornerstone of the forward strategy. Asia will see the rollout of a new women’s health product and expanded skincare offerings, while the U.S. will launch a gut health product suite, both intended to attract new consultants and customers. Management believes these efforts are critical for long-term growth but acknowledges the ramp will take time.
Catalysts in upcoming quarters
Over the next few quarters, we will closely monitor (1) the pace of consultant base rebuilding and compliance adaptation in China and Taiwan, (2) progress on digital marketing investments and the effectiveness of SaaS tools to boost online traffic and autoship rates, and (3) the rollout and uptake of new women’s health and gut health product lines in key markets. Additionally, the StockStory team will be tracking the execution of the U.S. direct selling relaunch and the company’s ability to identify and complete strategic acquisitions.
Nature's Sunshine currently trades at $10.09, down from $12.84 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High quality stocks for all market conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.